Cargando…
CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658279/ https://www.ncbi.nlm.nih.gov/pubmed/29076294 http://dx.doi.org/10.1002/psp4.12254 |
Ejemplares similares
-
Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
por: Patel, YT, et al.
Publicado: (2017) -
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015) -
Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022) -
Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014) -
Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)